BridgeBio Oncology Therapeutics Inc(BBOT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -1232.83 | Insider Own | 43.59% | Shs Outstand | 80.1M | Perf Week | -5.26% |
| Market Cap | 0.22B | Forward P/E | - | EPS next Y | 2.61% | Insider Trans | - | Shs Float | 45.2M | Perf Month | -34.15% |
| Enterprise Value | -0.01B | PEG | - | EPS next Q | -0.69 | Inst Own | 57.29% | Short Float | 8.5% | Perf Quarter | -66.63% |
| Income | -0.18B | P/S | - | EPS this Y | 39.87% | Inst Trans | 3.31% | Short Ratio | 7.17 | Perf Half Y | -67.9% |
| Sales | 0.00B | P/B | 0.67 | EPS next 5Y | 16.84% | ROA | -63.44% | Short Interest | 3.85M | Perf YTD | -78.43% |
| Book/sh | 4.03 | P/C | 0.96 | EPS past 3/5Y | -2681.49% -572.84% | ROE | -71.09% | 52W High | -81.84% ($14.87) | Perf Year | -76.66% |
| Cash/sh | 2.82 | P/FCF | - | Sales past 3/5Y | - | ROIC | -56.02% | 52W Low | 7.57% ($2.51) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -614363.93% | Gross Margin | - | Volatility(W/M) | 7.81% 7.51% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 0.26 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.69 | EPS Q/Q | -1803678.01% | Profit Margin | - | RSI (14) | 25.12 | Recom | 1.1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.69 | Sales Q/Q | - | SMA20 | -10.94% ($3.03) | Beta | 0.67 | Target Price | $20 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/8/11 | SMA50 | -47.37% ($5.13) | Rel Volume | 0.67 | Prev Close | $2.8 |
| Employees | 92 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | -24.81% - | SMA200 | -67% ($8.18) | Avg Volume(3M) | 0.54M | Price | $2.7 |
| IPO | 2024/2/9 | Option/Short | No/Yes | Trades | 2253 | Volume | 357,041 | Change | -3.57% |
🧬 BridgeBio Oncology Therapeutics (BBOT) is a clinical-stage precision oncology biotech developing targeted oncology drugs against the Ras and PI3Kα pathways. Spun off from BridgeBio Pharma, the company is raising outside capital to accelerate its independent pipeline, and is a U.S.-based drug developer with next-generation small-molecule candidates featuring KRas, panKRas, and Ras-PI3Kα inhibition mechanisms.
Over the past 1 year, on the lower side
82% below its 1-year high.
Traded less than usual. That is 67% of its average volume.
BBOT has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +39.9% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 57.3%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #294 of 594 in the industry
Based on market cap of $216M.
KROS#292 Keros Therapeutics Inc $225M PER - 
SLGL#293 Sol-Gel Technologies Ltd $225M PER - BBOT#294 BridgeBio Oncology Therapeutics Inc $216M PER - 
PLX#295 Protalix BioTherapeutics Inc $210M PER 11.5 
KRRO#296 Korro Bio Inc $209M PER - 
FAQ
What kind of company is BBOT?
BBOT belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of BBOT?
The market cap of BBOT is approximately $216M, ranking 3,962 within its sector.
What is the 52-week high and low for BBOT?
BBOT has recorded a 52-week high of $14.87 and a low of $2.51.
